中文

U.S. Stocks · Health Care · Free Data Page

ALNYLAM PHARMACEUTICALS, INC. ALNY

ALNYLAM PHARMACEUTICALS, INC.: FY2025 revenue $3.71B (+65.20% YoY); net income $313.7M; all 17 risk checks passed with 0 alerts.
Close Price$156.61Day +0.43%Market Cap$20.98BP/E66.9xFY2025 earningsP/B26.58xROE (FY2025)73.3%Avg. equity

Prices are closing data as of 2026-11-09, not real-time quotes. Metric definitions: P/E, P/B, ROE.

Want the full AI research report for ALNYLAM PHARMACEUTICALS, INC.?

This free page compiles public filings, financial ratios and risk screening. Generate a full research report to add business moat & competition, valuation scenarios, catalysts and bull/bear cases right at this URL.

New users who sign up free and verify their email receive 2 free credits for research reports or professional valuation.

10-Year FinancialsFY2016–2025

Key Multi-Year Facts

  • Revenue moved from $47.2M in FY2016 to $3.71B in FY2025 (9-year CAGR +62.4%).
  • Net income was negative in FY2016, FY2017, FY2018, FY2019, FY2020, FY2021, FY2022, FY2023, FY2024.

Latest 5 Fiscal Years

Fiscal Year20212022202320242025
Revenue (USD B)0.841.041.832.253.71
YoY71.3%22.9%76.2%23.0%65.2%
Net Income (USD B)-0.85-1.13-0.44-0.280.31
Operating Cash Flow (USD B)-0.64-0.540.10-0.010.52
ROE-106.3%——-414.6%73.3%
Gross Margin86.4%86.5%85.3%86.4%81.8%
Net Margin-101.0%-109.0%-24.1%-12.4%8.4%
Debt-to-Assets83.9%104.5%105.8%98.4%84.1%
Show all 10 fiscal years
Fiscal Year2016201720182019202020212022202320242025
Revenue (USD B)0.050.090.070.220.490.841.041.832.253.71
YoY—90.7%-16.7%193.4%124.3%71.3%22.9%76.2%23.0%65.2%
Net Income (USD B)-0.41-0.49-0.76-0.89-0.86-0.85-1.13-0.44-0.280.31
Operating Cash Flow (USD B)-0.31-0.38-0.56-0.28-0.61-0.64-0.540.10-0.010.52
ROE-44.6%-36.5%-49.6%-64.7%-69.9%-106.3%——-414.6%73.3%
Gross Margin—100.0%97.6%88.6%84.9%86.4%86.5%85.3%86.4%81.8%
Net Margin-869.6%-545.9%-1016.6%-403.2%-174.1%-101.0%-109.0%-24.1%-12.4%8.4%
Debt-to-Assets27.1%11.4%17.3%39.9%70.2%83.9%104.5%105.8%98.4%84.1%

Fiscal years follow the period-end calendar year (hover headers for period-end dates). ROE uses average beginning/ending equity. Source: SEC XBRL filings, compiled mechanically without AI. Official filings

Risk ChecklistAs of 2026-11-10

Rules-based screening using SEC XBRL financial data and 8-K/NT material event filings (no AI opinions).

0Alert 0Watch 15Pass 2N/A

Checked across financial quality, solvency, going concern, and SEC material filings (bankruptcy, delisting notice, auditor change, non-reliance, late filing) with no alerts or watch items triggered.

An "Alert" or "Watch" item flags a number that merits verification in primary filings, not a sell signal.

More U.S. data: 500 largest U.S. companies · U.S. high dividend stocks · Is the stock market open today?

Compiled mechanically from public filings and market quotes (data as of 2026-11-10). For informational purposes only, not investment advice.